anti-HER2 CAR macrophage therapy (Macera therapeutics)

N/A

Report date: 2025/06/11 10:41:57

Base Information

Drug Nameanti-HER2 CAR macrophage therapy (Macera therapeutics)
Drug Alias Namehuman HER2-targeted CAR-M cells (Macera therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Macrophages therapy
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsImmunostimulantsMacrophages stimulants
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Yuanmai Cell Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Yuanmai Cell Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A